INOVIQ Annual Report 2024

PRODUCT PORTFOLIO INOVIQ’s product portfolio includes in-market exosome research tools and an adjunct test for bladder cancer detection, clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and an early-stage exosome therapeutics program for solid tumours. COMMERCIAL UPDATE Commercial activities during the year focused on EXONET direct sales, partnering and conference activities. EXO-NET® PAN-EXOSOME CAPTURE EXO-NET pan-exosome capture is a research use only (RUO) tool for isolating exosomes from biofluids for biomarker discovery and diagnostic applications. EXONET offers speed, efficiency and scalability advantages over competitor exosome isolation products. EXO-NET Pan has been commercialised as an exosome isolation tool for sale in the rapidly growing exosome research market. EXO-NET Pan is manufactured by INOVIQ in 1.6mL, 1mL and 0.25mL pack sizes containing EXO-NET coated magnetic beads for processing up to 96, 60 or 15 samples. EXO-NET® 8 INOVIQ Limited Review of Operations continued 1. Adjunct to urine cytology to assist the detection of bladder cancer; 2. Umbrella Research & Option Agreement with University of Queensland Technology Research Tools Indication Use Discovery Verification Validation In-market Exosomes EXO-NET Multiple Pan-EV Capture Exosomes NEURO-NET Neurology Brain Derived-EV Capture Exosomes TEXO-NET Oncology Tumour Derived-EV Capture Diagnostics Indication Use Discovery Assay Development Clinical Validation In-market hTERT hTERT ICC1 Bladder Cancer Adjunct to Cytology SubB2M neuCA15-3 Breast Cancer Monitoring SubB2M neuCA125 Ovarian Cancer Monitoring Exosomes EXO-OC2 Ovarian Cancer Screening Therapeutics Indication Use Discovery Pre-clinical Clinical Approval Exosomes EEV-001 Breast Cancer CAR-Exosome therapy RUO RUO RUO LDT LDT IVD IVD-CLASS 1 USA

RkJQdWJsaXNoZXIy MjE2NDg3